NuVasive (NASDAQ: NUVA) and Cryolife (NYSE:CRY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
This table compares NuVasive and Cryolife’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares NuVasive and Cryolife’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NuVasive||$1.03 billion||2.52||$83.00 million||$1.16||43.68|
|Cryolife||$189.70 million||3.65||$3.70 million||$0.10||207.00|
NuVasive has higher revenue and earnings than Cryolife. NuVasive is trading at a lower price-to-earnings ratio than Cryolife, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
74.0% of Cryolife shares are held by institutional investors. 1.2% of NuVasive shares are held by insiders. Comparatively, 6.0% of Cryolife shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings for NuVasive and Cryolife, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NuVasive currently has a consensus target price of $68.21, indicating a potential upside of 34.62%. Cryolife has a consensus target price of $25.83, indicating a potential upside of 24.80%. Given NuVasive’s higher possible upside, analysts clearly believe NuVasive is more favorable than Cryolife.
Risk & Volatility
NuVasive has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Cryolife has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
NuVasive beats Cryolife on 8 of the 14 factors compared between the two stocks.
Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.
CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.